We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current LGND market cap is 2.15B. The company's latest EPS is USD -0.2094 and P/E is -532.86.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 28.1M | 30.98M | 41.53M | 51.81M | 42.81M |
| Operating Income | -3.36M | 2.99M | -19.1M | 10.96M | -2.39M |
| Net Income | 18.19M | 86.14M | -51.91M | -7.17M | -31.09M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 186.42M | 314.73M | 196.25M | 131.31M | 167.13M |
| Operating Income | 8.73M | 78.9M | 3.04M | 9.82M | -7.55M |
| Net Income | -2.99M | 57.14M | -33.36M | 52.15M | -4.03M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 787.22M | 913.87M | 866.41M | 954.87M | 941.77M |
| Total Liabilities | 86.3M | 107.35M | 91.21M | 113.69M | 111.34M |
| Total Equity | 700.91M | 806.52M | 775.2M | 841.18M | 830.44M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.36B | 1.3B | 762.67M | 787.22M | 941.77M |
| Total Liabilities | 652.76M | 476.43M | 165.18M | 86.3M | 111.34M |
| Total Equity | 709.53M | 821.16M | 597.49M | 700.91M | 830.44M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 49.58M | 18.73M | 32.05M | 68.58M | 97.05M |
| Investing | -11.68M | -3.78M | -58.53M | -105.04M | -143.66M |
| Financing | -59.95M | 12.18M | 21.67M | 76.75M | 97.14M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 54.59M | 78.8M | 137.85M | 49.58M | 97.05M |
| Investing | 231.65M | 30.52M | 163.62M | -11.68M | -143.66M |
| Financing | -310.55M | -137.76M | -275.99M | -59.95M | 97.14M |
| Market Cap | 2.15B |
| Price to Earnings Ratio | -532.86 |
| Price to Sales Ratio | 12.86 |
| Price to Cash Ratio | 29.71 |
| Price to Book Ratio | 2.59 |
| Dividend Yield | - |
| Shares Outstanding | 19.26M |
| Average Volume (1 week) | 139.44k |
| Average Volume (1 Month) | 137.63k |
| 52 Week Change | 61.39% |
| 52 Week High | 129.90 |
| 52 Week Low | 67.72 |
| Spread (Intraday) | 0.5 (0.45%) |
| Company Name | Ligand Pharmaceuticals Incorporated |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.ligand.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
